From GlobeNewswire: 2025-06-12 18:01:00

Celldex announced new data showing a sustained complete response and improved quality of life in patients with chronic spontaneous urticaria after 76 weeks. Barzolvolimab targets mast cells, with 41% of patients reporting a complete response and 48% stating their quality of life is no longer impacted by CSU. Enrollment for Phase 3 trials is ongoing, and the company will host a webcast today at 6:00 pm ET to discuss the results. The Phase 2 study showed rapid, profound improvements in UAS7 scores, with barzolvolimab demonstrating a well-tolerated safety profile throughout the study.



Read more at GlobeNewswire: Celldex Presents Unprecedented 76 Week Results from